Consegna Group (ASX: CGP) is building on the commercialisation potential of its BreatheAssist™ technology portfolio with the development of a new Elite Sports product designed specifically for athletes competing at the highest level internationally.
BreatheAssist™ is a device worn inside the nose that gently and independently dilates each of the nasal passages, increasing airflow.
BreatheAssist™ Elite Sports, a variant of the Consegna BreatheAssist™ technology, has been specifically developed with lightweight polymers to increase airflow and maintain a high level of comfort, fit and feel during exercise.
Fabio Pannuti chief executive of Consegna Group, commented on the positive news: "The monetisation of the BreatheAssist™ technology has now reached a significant stage.
"The confirmation of our regulatory pathway, identification of a commercial scale production process and feedback from consumers and athletes of the calibre of Mark O'Brien, has triggered a great deal of interest from commercial partners. We are on track to deliver an outcome for shareholders."
The design of the product follows a period of in-market testing with some of the world's leading sportspeople, including Australian cyclist Mark O'Brien.
O'Brien is using the BreatheAssist Elite Sports product in the Cycling Australia Subaru National Road Series which he is currently leading.
Dr Nick Ede, chief technology officer, said O'Brien's experience has been valuable in fine tuning the device and demonstrating its effectiveness with elite athletes.
Given the successful results and athlete experience, the BreatheAssist™ Elite Sports product is advancing to final clinical trials to gain further positive data to support this product in the market.
BreatheAssist™ market strategy
The technology is drawing closer to commercialisation, with an initial focus on the sports market where it has potential for performance improvement. In addition to sports, it has applications in the snoring, allergy management and drug delivery markets.
Consegna has previously secured regulatory clearance for its earlier BreatheAssist™ Sports product in the United States, Europe, UK and Australia, and is working towards the market launch.
The company believes the market for BreatheAssist™ Elite Sports goes beyond professional athletes, with amateur and social sport participants likely to benefit from the device.
The September quarter will be a busy one for Consegna as it works to complete the design of the BreatheAssist™ product for manufacture and scale-up.
The company will also be completing sports performance testing and undertake prelaunch activities as part of its Olympic program, as well as continuing licensing discussions with several multinational parties.
Proactive Investors is a market leader in the investment news space, providing ASX "Small and Mid-cap" company news, research reports, StockTube videos and One2One Investor Forums.